Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 3/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145106 | 0.99 | F10 (0.49) | F10L3MBTL1RXFP1KMT2ACCR2 | |
| SCHEMBL3153442 | 0.93 | L3MBTL1 (0.45) | F10L3MBTL1KMT2ACCR2CCR1 | |
| SCHEMBL3149703 | 0.91 | CCR2 (0.51) | L3MBTL1RXFP1KMT2ACCR2CCR1 | |
| SCHEMBL15103942 | 0.91 | CCR2 (0.49) | F10CCR2CCR1 | |
| SCHEMBL3148887 | 0.90 | CCR2 (0.53) | L3MBTL1RXFP1KMT2ACCR2CCR1 | |
| SCHEMBL15103981 | 0.90 | CCR2 (0.50) | F10L3MBTL1CCR2CCR1 | |
| SCHEMBL3148147 | 0.89 | CCR2 (0.49) | L3MBTL1RXFP1KMT2ACCR2SCN9A | |
| SCHEMBL3153878 | 0.89 | CCR2 (0.50) | L3MBTL1RXFP1KMT2ACCR2CCR1 | |
| SCHEMBL3157696 | 0.89 | CCR2 (0.51) | L3MBTL1RXFP1KMT2ACCR2CCR1 | |
| SCHEMBL3149459 | 0.87 | L3MBTL1 (0.49) | L3MBTL1RXFP1KMT2ACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | F10 597/4885L3MBTL1 3132/4885RXFP1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.